Cell Growth & Differentiation, Vol 3, Issue 11 839-846, Copyright © 1992 by American Association of Cancer Research

ARTICLES

Germ-line splicing mutation of the p53 gene in a cancer-prone family

SG Warneford, LJ Witton, ML Townsend, PB Rowe, RR Reddel, L Dalla-Pozza and G Symonds
Leukemia Research and Viral Pathology Unit, Children's Medical Research Institute, Westmead, New South Wales, Australia.

Li-Fraumeni syndrome is a rare autosomal dominant susceptibility to a variety of cancers including carcinomas of the breast and the adrenal cortex, tumors of brain and muscle tissue, and leukemias. Affected individuals develop cancer at a young age and often at multiple primary sites. A study has been conducted into the genetic basis of cancer in a particular Li-Fraumeni syndrome family. Examination of p53 as a candidate susceptibility gene revealed that, in two affected individuals, there was an aberrant larger transcript of 3.6 kilobases present in both tumor and constitutional material in addition to the normal-sized 2.8-kilobase transcript. The additional transcript was not found in three unaffected family members. S1 nuclease mapping localized the insertion toward the 5' end of the p53 transcript near exons 4 and 5, and sequencing revealed a point mutation in the splice donor site of intron 4 in the germ-line of the two affected individuals, which accounted for the presence of the larger transcript. The same splicing mutation was also detected in two obligate carriers and was not found in two unaffected individuals. As no mutations were detected in exons 5-8 in either tumor examined, the second p53 allele was most likely lost during tumorigenesis in both tumors. The demonstration of a germ-line splicing mutation in affected individuals from a Li-Fraumeni syndrome family provides for a novel mechanism of p53 inactivation not seen previously in other affected families, in whom the mutations have all been missense.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				C. A. French, J.-Y. Masson, C. S. Griffin, P. O'Regan, S. C. West, and J. Thacker Role of Mammalian RAD51L2 (RAD51C) in Recombination and Genetic Stability J. Biol. Chem., May 24, 2002; 277(22): 19322 - 19330. [Abstract] [Full Text] [PDF]

				K. E. Nichols, D. Malkin, J. E. Garber, J. F. Fraumeni Jr., and F. P. Li Germ-line p53 Mutations Predispose to a Wide Spectrum of Early-onset Cancers Cancer Epidemiol. Biomarkers Prev., February 1, 2001; 10(2): 83 - 87. [Abstract] [Full Text]

				G. J. Cote, E. S-C. Huang, W. Jin, and R. S. Morrison Sequence Requirements for Regulated RNA Splicing of the Human Fibroblast Growth Factor Receptor-1 alpha Exon J. Biol. Chem., January 10, 1997; 272(2): 1054 - 1060. [Abstract] [Full Text] [PDF]